

1.1 Facilities Maintenance and Engineering (FME)

OTS Directorate: Facilities Maintenance and Engineering (FME)							September 2002																																																																																																																																																											
OTS FME Director: William R. Lonergan							Customer Authorization: Dr. Craig Reynolds																																																																																																																																																											
NCI Director: Dr. Craig Reynolds																																																																																																																																																																		
<p align="center">Significant Events</p> <p>1. SOW signed and approved for Bldg. 470. Pre-bid walk-through for contractors to dismantle Bldg. 470 held 10/10/02; bids due 11/8/02.(W.O. 120005).</p> <p>2. First design review for CO2 Tank Replacement scheduled 10/25/02 (W.O. 118737).</p> <p>3. Clinical Proteomics Laboratory Cost and Schedule Location Analysis Report prepared by FME and submitted to the program on 9/20/02. The report compares cost and schedule between Invitrogen and Gaithersburg locations. Drawings of the Gaithersburg location are presently being reviewed.</p> <p>4. Bldg. 571, Phase 2, 2nd and 3rd Floor Renovation Scope has been confirmed with FME and LASP. A trend will be generated to include the design for Phase 2 under the current AE contract with Henry Adams. NCI and SAIC funding/finance have committed the additional design costs to the W.O. 113459 associated with Phase I.</p> <p>5. RFP's issued to four (4) potential sites. Responses received on 10/12/02. SAIC awaiting copies of responses (W.O. 118555).</p> <p>6. AHU drive components in Bldg. 459 have been replaced. All components are back to original manufacturer's specs.</p> <p>7. The 469 Terry Copeland Renovation was completed on 10/10/02, despite the late installation of the subcontracted new exterior window. (WO 118378)</p> <p>8. The DOC contractor completed the Lab 125 Lockett (RTP) portion of the 538 YPL Renovation on 10/10/02. Substantial completion inspection is scheduled for the morning of 10/14/02. (WO 119561)</p>							<p align="center">FME Open Work Orders (without VDF):</p> <table border="0"> <tr> <td>Original Budget</td> <td align="right">\$ 54.2 M</td> </tr> <tr> <td>+ Approved Scope Changes</td> <td align="right">\$ 5.3 M</td> </tr> <tr> <td>Current Budget</td> <td align="right">\$ 59.6 M</td> </tr> <tr> <td>+ Scope Changes (Pending Approval)</td> <td align="right">\$ 0.1 M</td> </tr> <tr> <td>+ Other Trend Changes</td> <td align="right">\$ 0.6 M</td> </tr> <tr> <td>Estimate at Completion</td> <td align="right">\$ 60.2 M</td> </tr> <tr> <td> Project to-date Cost</td> <td align="right"> \$ 19.9 M</td> </tr> <tr> <td>Project Approved Funding</td> <td align="right">\$ 50.4 M</td> </tr> </table> <p>Budget Notes:</p>				Original Budget	\$ 54.2 M	+ Approved Scope Changes	\$ 5.3 M	Current Budget	\$ 59.6 M	+ Scope Changes (Pending Approval)	\$ 0.1 M	+ Other Trend Changes	\$ 0.6 M	Estimate at Completion	\$ 60.2 M	 Project to-date Cost	 \$ 19.9 M	Project Approved Funding	\$ 50.4 M																																																																																																																																								
Original Budget	\$ 54.2 M																																																																																																																																																																	
+ Approved Scope Changes	\$ 5.3 M																																																																																																																																																																	
Current Budget	\$ 59.6 M																																																																																																																																																																	
+ Scope Changes (Pending Approval)	\$ 0.1 M																																																																																																																																																																	
+ Other Trend Changes	\$ 0.6 M																																																																																																																																																																	
Estimate at Completion	\$ 60.2 M																																																																																																																																																																	
 Project to-date Cost	 \$ 19.9 M																																																																																																																																																																	
Project Approved Funding	\$ 50.4 M																																																																																																																																																																	
<table border="1"> <thead> <tr> <th rowspan="2">OTS Director</th> <th rowspan="2">Schedule</th> <th rowspan="2">Budget</th> <th rowspan="2">Funding</th> <th rowspan="2">Customer</th> <th colspan="2">Overall</th> </tr> <tr> <th>Sep 02</th> <th>Aug 02</th> </tr> </thead> <tbody> <tr> <td>Applied/Developmental Research Support (ADRS)</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> </tr> <tr> <td>Biopharmaceutical Development Program (BDP)</td> <td align="center">Y</td> <td align="center">G</td> <td align="center">Y</td> <td align="center">G</td> <td align="center">Y</td> <td align="center">Y</td> </tr> <tr> <td>Vaccine Development Facility (VDF)</td> <td align="center">Y</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">Y</td> <td align="center">Y</td> </tr> <tr> <td>Basic Science Program (BSP)</td> <td align="center">G</td> <td align="center">G</td> <td align="center">Y</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> </tr> <tr> <td>Office of the Director (OD)</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> </tr> <tr> <td>Research Technology Program (RTP)</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> </tr> <tr> <td>Laboratory Animal Sciences Program (LASP)</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> </tr> <tr> <td>Charles River Laboratories (CRL)</td> <td align="center">G</td> <td align="center">G</td> <td align="center">R</td> <td align="center">G</td> <td align="center">Y</td> <td align="center">Y</td> </tr> <tr> <td>Summary Assessment</td> <td align="center">G</td> <td align="center">G</td> <td align="center">Y</td> <td align="center">G</td> <td align="center">G</td> <td align="center">G</td> </tr> </tbody> </table>							OTS Director	Schedule	Budget	Funding	Customer	Overall		Sep 02	Aug 02	Applied/Developmental Research Support (ADRS)	G	G	G	G	G	G	Biopharmaceutical Development Program (BDP)	Y	G	Y	G	Y	Y	Vaccine Development Facility (VDF)	Y	G	G	G	Y	Y	Basic Science Program (BSP)	G	G	Y	G	G	G	Office of the Director (OD)	G	G	G	G	G	G	Research Technology Program (RTP)	G	G	G	G	G	G	Laboratory Animal Sciences Program (LASP)	G	G	G	G	G	G	Charles River Laboratories (CRL)	G	G	R	G	Y	Y	Summary Assessment	G	G	Y	G	G	G	<p align="center">WO's > \$1M:</p> <table border="1"> <thead> <tr> <th>WO#</th> <th>BLDG</th> <th>BAC</th> <th>EAC</th> <th>FUNDS</th> </tr> </thead> <tbody> <tr><td>1.</td><td>119691 - 376</td><td>\$ 7.9</td><td>\$ 7.9</td><td>\$ 7.9</td></tr> <tr><td>2.</td><td>119561 - 538</td><td>\$ 1.2</td><td>\$ 1.3</td><td>\$ 1.0</td></tr> <tr><td>3.</td><td>119250 - 560</td><td>\$ 1.6</td><td>\$ 1.6</td><td>\$ 1.5</td></tr> <tr><td>4.</td><td>118050 - 560</td><td>\$ 1.4</td><td>\$ 1.4</td><td>\$ 1.4</td></tr> <tr><td>5.</td><td>117964 - 552</td><td>\$ 1.9</td><td>\$ 1.9</td><td>\$ 1.8</td></tr> <tr><td>6.</td><td>116450 - 322</td><td>\$ 2.8</td><td>\$ 2.8</td><td>\$ 2.8</td></tr> <tr><td>7.</td><td>116343 -1047</td><td>\$ 1.2</td><td>\$ 1.2</td><td>\$ 1.2</td></tr> <tr><td>8.</td><td>116345 - 434</td><td>\$ 4.9</td><td>\$ 4.9</td><td>\$ 1.0 *</td></tr> <tr><td>9.</td><td>113459 - 571</td><td>\$ 2.8</td><td>\$ 2.8</td><td>\$ 2.8</td></tr> <tr><td>10.</td><td>115929 - 538</td><td>\$ 4.8</td><td>\$ 4.9</td><td>\$ 4.9</td></tr> <tr><td>11.</td><td>112693 - 325</td><td>\$ 3.8</td><td>\$ 3.7</td><td>\$ 3.9</td></tr> <tr><td>12.</td><td>115093 - 560</td><td>\$ 3.1</td><td>\$ 2.9</td><td>\$ 2.9</td></tr> <tr><td>13.</td><td>114227 - 915</td><td>\$ 1.4</td><td>\$ 1.5</td><td>\$ 1.5</td></tr> <tr><td>14.</td><td>119906 - CRL</td><td>\$ 7.5</td><td>\$ 7.5</td><td>\$ 4.9 *</td></tr> <tr><td>15.</td><td>118555 - VDF</td><td>\$ 64.9</td><td>\$ 64.9</td><td>\$ 14.2 *</td></tr> </tbody> </table> <p align="right">*Incremental Funding</p>				WO#	BLDG	BAC	EAC	FUNDS	1.	119691 - 376	\$ 7.9	\$ 7.9	\$ 7.9	2.	119561 - 538	\$ 1.2	\$ 1.3	\$ 1.0	3.	119250 - 560	\$ 1.6	\$ 1.6	\$ 1.5	4.	118050 - 560	\$ 1.4	\$ 1.4	\$ 1.4	5.	117964 - 552	\$ 1.9	\$ 1.9	\$ 1.8	6.	116450 - 322	\$ 2.8	\$ 2.8	\$ 2.8	7.	116343 -1047	\$ 1.2	\$ 1.2	\$ 1.2	8.	116345 - 434	\$ 4.9	\$ 4.9	\$ 1.0 *	9.	113459 - 571	\$ 2.8	\$ 2.8	\$ 2.8	10.	115929 - 538	\$ 4.8	\$ 4.9	\$ 4.9	11.	112693 - 325	\$ 3.8	\$ 3.7	\$ 3.9	12.	115093 - 560	\$ 3.1	\$ 2.9	\$ 2.9	13.	114227 - 915	\$ 1.4	\$ 1.5	\$ 1.5	14.	119906 - CRL	\$ 7.5	\$ 7.5	\$ 4.9 *	15.	118555 - VDF	\$ 64.9	\$ 64.9	\$ 14.2 *
OTS Director	Schedule	Budget	Funding	Customer	Overall																																																																																																																																																													
					Sep 02	Aug 02																																																																																																																																																												
Applied/Developmental Research Support (ADRS)	G	G	G	G	G	G																																																																																																																																																												
Biopharmaceutical Development Program (BDP)	Y	G	Y	G	Y	Y																																																																																																																																																												
Vaccine Development Facility (VDF)	Y	G	G	G	Y	Y																																																																																																																																																												
Basic Science Program (BSP)	G	G	Y	G	G	G																																																																																																																																																												
Office of the Director (OD)	G	G	G	G	G	G																																																																																																																																																												
Research Technology Program (RTP)	G	G	G	G	G	G																																																																																																																																																												
Laboratory Animal Sciences Program (LASP)	G	G	G	G	G	G																																																																																																																																																												
Charles River Laboratories (CRL)	G	G	R	G	Y	Y																																																																																																																																																												
Summary Assessment	G	G	Y	G	G	G																																																																																																																																																												
WO#	BLDG	BAC	EAC	FUNDS																																																																																																																																																														
1.	119691 - 376	\$ 7.9	\$ 7.9	\$ 7.9																																																																																																																																																														
2.	119561 - 538	\$ 1.2	\$ 1.3	\$ 1.0																																																																																																																																																														
3.	119250 - 560	\$ 1.6	\$ 1.6	\$ 1.5																																																																																																																																																														
4.	118050 - 560	\$ 1.4	\$ 1.4	\$ 1.4																																																																																																																																																														
5.	117964 - 552	\$ 1.9	\$ 1.9	\$ 1.8																																																																																																																																																														
6.	116450 - 322	\$ 2.8	\$ 2.8	\$ 2.8																																																																																																																																																														
7.	116343 -1047	\$ 1.2	\$ 1.2	\$ 1.2																																																																																																																																																														
8.	116345 - 434	\$ 4.9	\$ 4.9	\$ 1.0 *																																																																																																																																																														
9.	113459 - 571	\$ 2.8	\$ 2.8	\$ 2.8																																																																																																																																																														
10.	115929 - 538	\$ 4.8	\$ 4.9	\$ 4.9																																																																																																																																																														
11.	112693 - 325	\$ 3.8	\$ 3.7	\$ 3.9																																																																																																																																																														
12.	115093 - 560	\$ 3.1	\$ 2.9	\$ 2.9																																																																																																																																																														
13.	114227 - 915	\$ 1.4	\$ 1.5	\$ 1.5																																																																																																																																																														
14.	119906 - CRL	\$ 7.5	\$ 7.5	\$ 4.9 *																																																																																																																																																														
15.	118555 - VDF	\$ 64.9	\$ 64.9	\$ 14.2 *																																																																																																																																																														
<p align="center">Major Areas of Concern:</p> <p>1. Bldg. 470 Anthrax/indemnity issue to be resolved for Phase I, II and III. Need funding for Phase II and III (W.O. 120005).</p> <p>2. RTP has set a high priority for the PEL Trailer delivery. Award of trailer pending NC COA (W.O. 119531).</p> <p>3. Renovation of Tollhouse Suite 209 will require \$195,000 additional funding that was reprogrammed for equipment procurement (W.O. 119054).</p> <p>4. NCI has the action to request a waiver for the construction of Bldg. 461 and the submittal of the NEPA package to NIH (W.O. 119567).</p> <p>5. The FA estimate has resulted in the need for additional funding for the revised scope of work for the fire protection sprinkler system for Buildings 576 and 578. CCR to confirm funding status. (WO 117938/118881)</p> <p>6. Bldg. 571 Phase I schedule will be impacted by the additional time required for COA approval (W.O. 113459).</p>							<p>Director's G On Track</p> <p>Overall Y Caution</p> <p>Assessment: R Needs Attention</p> <p>N/A Not Applicable/On Hold/Prior to CA</p>																																																																																																																																																											